Overview

Price chart · mood · technical indicators

XGN

Exagen Incstock Healthcare

Diagnostics & Research

$3.1051.71%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$2.59$12.23

Current: $3.10

Idea: EMA

1Y Return

+76.1%

Sharpe 3Y

1.04

Market Comparison

vs Healthcare Sector & Diagnostics & Research Industry

XGN

-51.71%

1Y Performance

Healthcare

Sector 1Y

Diagnostics & Research

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.930.0% YoY

Profit margin-30.0%HEALTHCARE

Market cap$73.9MMicro cap

Wall Street coverage

$8.67median target· current $1.38 (+528.3%)7 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 4.23
P/S (TTM): 1.11
EV/EBITDA: -0.16

Profitability & growth

ROE (TTM): -147.8%
Operating margin: -29.9%
Revenue growth YoY: 21.8%
Dividend yield: —
Beta: 1.94

Last earnings

Mar 23, 2026 · Estimate $-0.18 · Reported $-0.27

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Exagen Inc

Company profile

Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.

Classification

Sector: Healthcare
Industry: Diagnostics & Research
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 1261 LIBERTY WAY, VISTA, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$73.9M

Shares outstanding$24.1M

52W high$12.23

52W low$2.59

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

XGN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

annualreportproof.htm

Exagen (NASDAQ: XGN) outlines 2026 shareholder meeting, board elections and say-on-pay

Exagen (XGN) to Release Quarterly Earnings on Monday

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen schedules May 11 earnings call before market open, 8:30 ET

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest

Exagen Announces Board Resignation and Committee Restructuring

Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts

Exagen Announces Board Resignation and Committee Restructuring

Ana Hooker resigns from Exagen Board; board size falls to seven

Board reshuffle at Exagen (NASDAQ: XGN) as Ana Hooker steps down

Exagen (NASDAQ: XGN) director reports 7,500 restricted stock units

XGN Maintained by Canaccord Genuity -- Price Target Lowered to $8.00

Exagen (NasdaqGM:XGN) Stock Forecast & Analyst Predictions

Does Exagen (XGN)’s 200%+ upside potential make it one of the best penny stocks set to explode?

Exagen announces resale of up to 1.15M shares

Exagen Inc stock (US30063K1051): Is its autoimmune testing edge strong enough to unlock new upside?

About Exagen Inc

Classification

Company profile

XGN

Market Comparison

XGN Market Analysis

Overview

XGN

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

annualreportproof.htm

Exagen (NASDAQ: XGN) outlines 2026 shareholder meeting, board elections and say-on-pay

Exagen (XGN) to Release Quarterly Earnings on Monday

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen schedules May 11 earnings call before market open, 8:30 ET

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest

Exagen Announces Board Resignation and Committee Restructuring

Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts

Exagen Announces Board Resignation and Committee Restructuring

Ana Hooker resigns from Exagen Board; board size falls to seven

Board reshuffle at Exagen (NASDAQ: XGN) as Ana Hooker steps down

Exagen (NASDAQ: XGN) director reports 7,500 restricted stock units

XGN Maintained by Canaccord Genuity -- Price Target Lowered to $8.00

Exagen (NasdaqGM:XGN) Stock Forecast & Analyst Predictions

Does Exagen (XGN)’s 200%+ upside potential make it one of the best penny stocks set to explode?

Exagen announces resale of up to 1.15M shares

Exagen Inc stock (US30063K1051): Is its autoimmune testing edge strong enough to unlock new upside?

About Exagen Inc

Classification

Company profile

XGN

Market Comparison